Cargando…

Pour une prise en charge préventive de la maladie d’Alzheimer()

Dementias, and Alzheimer's disease (AD) in particular, will increasingly become a public health issue. However, three major data may change the severity of these pathologies: in young adults, simple measures of healthy lifestyle (control of vascular risk factors, physical activity and cognitive...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubois, B., Bombois, S., Villain, N., Teichmann, M., Epelbaum, S., Migliaccio, R., Genthon, R., Verrat, B., Lesoil, C., Levy, M., Le Ber, I., Levy, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172758/
https://www.ncbi.nlm.nih.gov/pubmed/32322104
http://dx.doi.org/10.1016/j.banm.2020.04.012
_version_ 1783524319036440576
author Dubois, B.
Bombois, S.
Villain, N.
Teichmann, M.
Epelbaum, S.
Migliaccio, R.
Genthon, R.
Verrat, B.
Lesoil, C.
Levy, M.
Le Ber, I.
Levy, R.
author_facet Dubois, B.
Bombois, S.
Villain, N.
Teichmann, M.
Epelbaum, S.
Migliaccio, R.
Genthon, R.
Verrat, B.
Lesoil, C.
Levy, M.
Le Ber, I.
Levy, R.
author_sort Dubois, B.
collection PubMed
description Dementias, and Alzheimer's disease (AD) in particular, will increasingly become a public health issue. However, three major data may change the severity of these pathologies: in young adults, simple measures of healthy lifestyle (control of vascular risk factors, physical activity and cognitive stimulation), have an impact on a future cognitive decline; the same lifestyle interventions may delay the start of the disease for elderly people potentially at-risk; finally, and for the first time, a monoclonal antibody directed against amyloid lesions has just shown a significant effect on the progression of AD in patients at an early stage of the disease. According to these results, we will have to reconsider the strategy for managing minor or severe cognitive disorders and particularly AD. Nowadays, patients start the care process too late. The solution is to act earlier, even preventively. It is necessary to improve a care offer adapted to this new situation in order to impact on the disease as soon as possible, even before the onset of symptoms, based on: 1) predictive algorithms aimed at establishing whose cognitively unimpaired individuals may further develop the disease; these algorithms will be based on demographic, family, cognitive, genomic and biological data, such as in the “Santé Cerveau” project developed in partnership with the Health Regional Agency (ARS) and the general practitioners; 2)and on some expert centers which must become “dementia prevention clinics” to test prevention measures, initiate and validate multi-domain therapeutic education programs; to disclose about the risk in response to the request of worried patients; and to propose early pharmacological treatments if these individuals are on the way to declare AD in the coming months, taking into account competition between risks. This will allow to prepare to make use of new pharmacological treatments that might be discovered.
format Online
Article
Text
id pubmed-7172758
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine.
record_format MEDLINE/PubMed
spelling pubmed-71727582020-04-22 Pour une prise en charge préventive de la maladie d’Alzheimer() Dubois, B. Bombois, S. Villain, N. Teichmann, M. Epelbaum, S. Migliaccio, R. Genthon, R. Verrat, B. Lesoil, C. Levy, M. Le Ber, I. Levy, R. Bull Acad Natl Med Revue Générale Dementias, and Alzheimer's disease (AD) in particular, will increasingly become a public health issue. However, three major data may change the severity of these pathologies: in young adults, simple measures of healthy lifestyle (control of vascular risk factors, physical activity and cognitive stimulation), have an impact on a future cognitive decline; the same lifestyle interventions may delay the start of the disease for elderly people potentially at-risk; finally, and for the first time, a monoclonal antibody directed against amyloid lesions has just shown a significant effect on the progression of AD in patients at an early stage of the disease. According to these results, we will have to reconsider the strategy for managing minor or severe cognitive disorders and particularly AD. Nowadays, patients start the care process too late. The solution is to act earlier, even preventively. It is necessary to improve a care offer adapted to this new situation in order to impact on the disease as soon as possible, even before the onset of symptoms, based on: 1) predictive algorithms aimed at establishing whose cognitively unimpaired individuals may further develop the disease; these algorithms will be based on demographic, family, cognitive, genomic and biological data, such as in the “Santé Cerveau” project developed in partnership with the Health Regional Agency (ARS) and the general practitioners; 2)and on some expert centers which must become “dementia prevention clinics” to test prevention measures, initiate and validate multi-domain therapeutic education programs; to disclose about the risk in response to the request of worried patients; and to propose early pharmacological treatments if these individuals are on the way to declare AD in the coming months, taking into account competition between risks. This will allow to prepare to make use of new pharmacological treatments that might be discovered. Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine. 2020-06 2020-04-21 /pmc/articles/PMC7172758/ /pubmed/32322104 http://dx.doi.org/10.1016/j.banm.2020.04.012 Text en © 2020 Published by Elsevier Masson SAS on behalf of l'Académie nationale de médecine. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Revue Générale
Dubois, B.
Bombois, S.
Villain, N.
Teichmann, M.
Epelbaum, S.
Migliaccio, R.
Genthon, R.
Verrat, B.
Lesoil, C.
Levy, M.
Le Ber, I.
Levy, R.
Pour une prise en charge préventive de la maladie d’Alzheimer()
title Pour une prise en charge préventive de la maladie d’Alzheimer()
title_full Pour une prise en charge préventive de la maladie d’Alzheimer()
title_fullStr Pour une prise en charge préventive de la maladie d’Alzheimer()
title_full_unstemmed Pour une prise en charge préventive de la maladie d’Alzheimer()
title_short Pour une prise en charge préventive de la maladie d’Alzheimer()
title_sort pour une prise en charge préventive de la maladie d’alzheimer()
topic Revue Générale
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172758/
https://www.ncbi.nlm.nih.gov/pubmed/32322104
http://dx.doi.org/10.1016/j.banm.2020.04.012
work_keys_str_mv AT duboisb pourunepriseenchargepreventivedelamaladiedalzheimer
AT bomboiss pourunepriseenchargepreventivedelamaladiedalzheimer
AT villainn pourunepriseenchargepreventivedelamaladiedalzheimer
AT teichmannm pourunepriseenchargepreventivedelamaladiedalzheimer
AT epelbaums pourunepriseenchargepreventivedelamaladiedalzheimer
AT migliaccior pourunepriseenchargepreventivedelamaladiedalzheimer
AT genthonr pourunepriseenchargepreventivedelamaladiedalzheimer
AT verratb pourunepriseenchargepreventivedelamaladiedalzheimer
AT lesoilc pourunepriseenchargepreventivedelamaladiedalzheimer
AT levym pourunepriseenchargepreventivedelamaladiedalzheimer
AT leberi pourunepriseenchargepreventivedelamaladiedalzheimer
AT levyr pourunepriseenchargepreventivedelamaladiedalzheimer